Bigfoot Biomedical announced today that it established a team led by Berkley Nelson to lead the company’s sales effort.
Bigfoot will be marketing the Bigfoot Unity real-time, dose-decision support system, which uses smartpen caps and integrates Abbott’s FreeStyle Libre 2 continuous glucose monitoring platform. Bigfoot Unity has been submitted for FDA clearance.
Nelson, currently a senior VP at the company, will lead the commercial team when it begins to contract with healthcare providers and payers, according to a news release. In addition to Nelson, Tony Galliani joins as VP of sales, while Sam Auderer has been appointed director of commercial operations.
“The Bigfoot team has done an incredible job with a tremendous amount of fresh thinking to get the product to this point,” Nelson said in the release. “Now I’ve embraced the challenge of designing the commercial model that will put the Bigfoot Unity program into the hands of the people who need it. There are many innovations coming out for insulin pump users but few for people who are under multiple daily injection (MDI) therapy, so we’re excited to deliver a solution for this underserved market. At a startup, you often get the opportunity to break the norms, which is exactly what Bigfoot aims to do.”
Nelson and Auderer previously worked in similar capacities at Voluntis, while Galliani holds more than two decades of experience in the diabetes device industry, having most recently served as VP of sales at Companion Medical.
“It’s exciting to transition our energies from FDA submission of our Bigfoot Unity diabetes management system to building out key support functions within our organization,” Bigfoot CEO Jeffrey Brewer said. “As commercial SVP, Berkley will be instrumental in standing up the commercial operations and driving adoption by providers. He will also craft innovative reimbursement strategies to provide accessibility to the Bigfoot Unity solution to the millions of people with type 1 and type 2 diabetes who struggle with the constant decision-making around insulin dosing.”